Publications by authors named "Deanna Merrill"

Claim this Profile
P
PAIRED: Quantitative and Qualitative PAtIent-Reported Experiences and perceiveD Benefit of Treatment with Dolutegravir/Lamivudine in the United States.
Jihad Slim, Andrew P Brogan, Gavin Harper, Katie Mycock, Abigail McMillan, Deanna Merrill

Patient· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes and Perspectives of People With Human Immunodeficiency Virus Type 1 Twelve Months After Initiation of Long-acting Cabotegravir and Rilpivirine in an Observational Real-world US Study (BEYOND).
Dima Dandachi, Cindy Garris, David Richardson, Gary Sinclair, Doug Cunningham, Deanna Merrill

Open Forum Infect Dis· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Association of the Microbiome with Melanoma Tumor Response to Immune Checkpoint Inhibitor Treatment and Immune-Related Adverse Events (NCT05102773).
Caroline Dravillas, Nyelia Williams, Marium Husain, Rebecca Hoyd, Ahmed Hussein, Deanna Merrill

medRxiv· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabotegravir + Rilpivirine Long-Acting: Overview of Injection Guidance, Injection Site Reactions, and Best Practices for Intramuscular Injection Administration.
Paula Teichner, Nadine Chamay, Emilie Elliot, Miguel Pascual-Bernáldez, Deanna Merrill

Open Forum Infect Dis· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study.
Stefan Schneider, Gary Blick, Christina Burke, Douglas Ward, Paul Benson, Deanna Merrill

Infect Dis Ther· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Effectiveness of Dolutegravir/Lamivudine in People With HIV-1 in Test-and-Treat Settings or With High Baseline Viral Loads: TANDEM Study Subgroup Analyses.
Paul Benson, Jennifer Kuretski, Cynthia Donovan, Gavin Harper, Deanna Merrill

Infect Dis Ther· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks.
Charlotte-Paige Rolle, Mezgebe Berhe, Tulika Singh, Roberto Ortiz, Anson Wurapa, Deanna Merrill

Open Forum Infect Dis· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation-effectiveness study (CUSTOMIZE).
Maggie Czarnogorski, Cindy P Garris, Marybeth Dalessandro, Ronald D'Amico, Toyin Nwafor, Deanna Merrill

J Int AIDS Soc· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study.
Cindy P Garris, Maggie Czarnogorski, Marybeth Dalessandro, Ronald D'Amico, Toyin Nwafor, Deanna Merrill

J Int AIDS Soc· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV.
Charlotte-Paige Rolle, Mezgebe Berhe, Tulika Singh, Roberto Ortiz, Anson Wurapa, Deanna Merrill

AIDS· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Review of medical encounters in the 5 years before a diagnosis of HIV-1 infection: implications for early detection.
Daniel Klein, Leo B Hurley, Deanna Merrill, Charles P Quesenberry,

J Acquir Immune Defic Syndr· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis